Clinical Trial: Sitogilun Malate Plus Amlodipine in Patients With Hypertension and Risk of Early Kidney Damage

U.S., Oct. 16 -- ClinicalTrials.gov registry received information related to the study (NCT07876544) titled 'Sitogilun Malate Plus Amlodipine in Patients With Hypertension and Risk of Early Kidney Damage' on Oct. 09.

Brief Summary: This is a multicenter, randomized, double-blind, parallel-controlled Phase IV clinical trial designed to evaluate the efficacy and safety of sitogilun malate tablets in combination with amlodipine besylate tablets in patients with mild to moderate essential hypertension and risk of early kidney damage. Approximately 456 eligible participants will be randomized in a 1:1:1 ratio to receive sitogilun malate plus amlodipine, allisartan isoproxil plus amlodipine, or placebo plus amlodipine for 8 weeks. The primary ef...